Activation of p38MAPK contributes to expanded polyglutamine-induced cytotoxicity

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Tsirigotis, Maria ^a   Baldwin, R Mitchell ^a,b   Tang, Matthew Y ^a,b   Lorimer, Ian A J ^a,b   Gray, Douglas A ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYGLUTAMINE; PROTEIN KINASE C IOTA; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4-(4-FLUOROPHENYL)-2-(4-HYDROXYPHENYL)-5-(4-PYRIDYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDINYL)IMIDAZO(2,1 B)THIAZOLE; 6-(4-FLUOROPHENYL)-2,3-DIHYDRO-5-(4-PYRIDINYL)IMIDAZO(2,1-B)THIAZOLE; ATAXIN 1; ATAXIN-1; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; ISOENZYME; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE; PROTEIN KINASE C; PROTEIN KINASE C LAMBDA; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PROTEIN DEPLETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPINOCEREBELLAR DEGENERATION; ANIMAL; CELL DEATH; CELL LINE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYME INDUCTION; GENETICS; METABOLISM; RABBIT; TRANSGENIC MOUSE;

ANIMALS; CELL DEATH; CELL LINE; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; ISOENZYMES; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES; PROTEIN KINASE C; PYRIDINES; RABBITS; RNA INTERFERENCE; THIAZOLES;

EID: 47749118777     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002130     Document Type: Article

References (89)

1. Everett CM, Wood NW (2004) Trinucleotide repeats and neurodegenerative disease. Brain 127: 2385-2405.
2. Jana NR, Nukina N (2003) Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitinproteasome pathway. J Chem Neuroanat 26: 95-101.
3. Ross CA (1997) Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19: 1147-1150.
4. Landles C, Bates GP (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 5: 958-963.
5. Rangone H, Pardo R, Colin E, Girault JA, Saudou F, et al. (2005) Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits polyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J Biol Chem 280: 22021-22028.
6. Sugars KL, Brown RJ, Cook L, Swartz J, Rubinsztein DC (2004) Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis. J Biol Chem 279: 4988-4999.
7. Sherman MY, Goldberg AL (2001) Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 29: 15-32.
8. Kuida K, Boucher DM (2004) Functions of MAP kinases: insights from genetargeting studies. J Biochem (Tokyo) 135: 653-656.
9. Johnson GL, Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912.
10. Torii S, Nakayama K, Yamamoto T, Nishida E (2004) Regulatory mechanisms and function of ERK MAP kinases. J Biochem (Tokyo) 136: 557-561.
11. Harper SJ, LoGrasso P (2001) Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal 13: 299-310.
12. Kolch W (2005) Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6: 827-837.
13. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, et al. (2004) JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101: 665-670.
14. Silva RM, Kuan CY, Rakic P, Burke RE (2005) Mixed lineage kinase-c-jun N-terminal kinase signaling pathway: a new therapeutic target in Parkinson's disease. Mov Disord 20: 653-664.
15. Song C, Perides G, Liu YF (2002) Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem 277: 6703-6707.
16. Li SH, Cheng AL, Li H, Li XJ (1999) Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin. J Neurosci 19: 5159-5172.
17. Charroux B, Freeman M, Kerridge S, Baonza A (2006) Atrophin contributes to the negative regulation of epidermal growth factor receptor signaling in Drosophila. Dev Biol 291: 278-290.
18. Lievens J-C, Rival T, Iche M, Chneiweiss H, Birman S (2005) Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet 14: 713-724.
19. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, et al. (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 15: 273-285.
20. Miller VM, Nelson RF, Gouvion CM, Williams A, Rodriguez-Lebron E, et al. (2005) CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J Neurosci 25: 9152-9161.
21. Senut MC, Suhr ST, Kaspar B, Gage FH (2000) Intraneuronal aggregate formation and cell death after viral expression of expanded polyglutamine tracts in the adult rat brain. J Neurosci 20: 219-229.
22. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118: 127-138.
23. Miyashita T, Tabuchi A, Fukuchi M, Hara D, Kisukeda T, et al. (2005) Interference with activity-dependent transcriptional activation of BDNF gene depending upon the expanded polyglutamines in neurons. Biochem Biophys Res Commun 333: 1241-1248.
24. Humbert S, Bryson EA, Cordelieres FP, Connors NC, Datta SR, et al. (2002) The IGF-1/Akt Pathway Is Neuroprotective in Huntington's Disease and Involves Huntingtin Phosphorylation by Akt. Developmental Cell 2: 831-837.
25. Vig PJS, Subramony SH, D'Souza DR, Wei J, Lopez ME (2006) Intranasal administration of IGF-I improves behavior and Purkinje cell pathology in SCA1 mice. Brain Research Bulletin 69: 573-579.
26. Laurino L, Wang XX, de la Houssaye BA, Sosa L, Dupraz S, et al. (2005) PI3K activation by IGF-1 is essential for the regulation of membrane expansion at the nerve growth cone. J Cell Sci 118: 3653-3662.
27. Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL (2005) A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 105: 4429-4436.
28. Zheng W-H, Quirion R (2004) Comparative signaling pathways of insulin-like growth factor-1 and brain-derived neurotrophic factor in hippocampal neurons and the role of the PI3 kinase pathway in cell survival. Journal of Neurochemistry 89: 844-852.
29. Yu X-R, Jia G-R, Gao G-D, Wang S-H, Han Y, et al. (2006) Neuroprotection of Insulin against Oxidative Stress-induced Apoptosis in Cultured Retinal Neurons: Involvement of Phosphoinositide 3-kinase/Akt Signal Pathway. Acta Biochimica et Biophysica Sinica 38: 241-248.
30. Li B-S, Ma W, Jaffe H, Zheng Y, Takahashi S, et al. (2003) Cyclin-dependent Kinase-5 Is Involved in Neuregulin-dependent Activation of Phosphatidylinositol 3-Kinase and Akt Activity Mediating Neuronal Survival. J Biol Chem 278: 35702-35709.
31. Nakazawa T, Shimura M, Tomita H, Akiyama H, Yoshioka Y, et al. (2003) Intrinsic activation of PI3K/Akt signaling pathway and its neuroprotective effect against retinal injury. Current Eye Research 26: 55-63.
32. Campbell CSG, Caperuto LC, Hirata AE, Araujo EP, Velloso LA, et al. (2004) The phosphatidylinositol/AKT/atypical PKC pathway is involved in the improved insulin sensitivity by DHEA in muscle and liver of rats in vivo. Life Sciences 76: 57-70.
33. Antonella Muscella SG, Maria Giovanna Elia, Carlo Storelli, Santo Marsigliante (2004) Differential signalling of purinoceptors in HeLa cells through the extracellular signal-regulated kinase and protein kinase C pathways. Journal of Cellular Physiology 200: 428-439.
34. Bandyopadhyay G, Standaert ML, Sajan MP, Kanoh Y, Miura A, et al. (2004) Protein Kinase C-{lambda} Knockout in Embryonic Stem Cells and Adipocytes Impairs Insulin-Stimulated Glucose Transport. Mol Endocrinol 18: 373-383.
35. Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, et al. (2005) Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet 14: 1569-1577.
36. Kaytor MD, Byam CE, Tousey SK, Stevens SD, Zoghbi HY, et al. (2005) A cell-based screen for modulators of ataxin-1 phosphorylation. Hum Mol Genet 14: 1095-1105.
37. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, et al. (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82: 937-948.
38. Baldwin RM, Garratt-Lalonde M, Parolin DAE, Krzyzanowski PM, Andrade MA, et al. (2005) Protection of glioblastoma cells from cisplatin cytotoxicity via protein kinase C [iota]-mediated attenuation of p38 MAP kinase signaling. Oncogene 25: 2909-2919.
39. Wu C-j, Chen Z, Ullrich A, Greene MI, O'Rourke DM (2000) Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by Signal-Regulatory Proteins (SIRPs). Oncogene 19: 3999.
40. Swayne LA, Chen L, Hameed S, Barr W, Charlesworth E, et al. (2005) Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. Molecular and Cellular Neuroscience 30: 339-351.
41. Cha J-HJ, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, et al. (1998) Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proceedings of the National Academy of Sciences 95: 6480-6485.
42. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, et al. (1999) Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington's Disease Mutation. J Neurosci 19: 3248-3257.
43. Regala RP, Weems C, Jamieson L, Khoor A, Edell ES, et al. (2005) Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 65: 8905-8911.
44. Colognato R, Laurenza I, Fontana I, Coppede F, Siciliano G, et al. (2006) Modulation of hydrogen peroxide-induced DNA damage, MAPKs activation and cell death in PC12 by ergothioneine. Clin Nutr 25: 135-145.
45. Papoutsaki M, Moretti F, Lanza M, Marinari B, Sartorelli V, et al. (2005) A p38-dependent pathway regulates DeltaNp63 DNA binding to p53-dependent promoters in UV-induced apoptosis of keratinocytes. Oncogene 24: 6970-6975.
46. Nolan Y, Vereker E, Lynch AM, Lynch MA (2003) Evidence that lipopolysaccharide-induced cell death is mediated by accumulation of reactive oxygen species and activation of p38 in rat cortex and hippocampus. Exp Neurol 184: 794-804.
47. Bodles AM, Barger SW (2005) Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol Aging 26: 9-16.
48. Puig B, Gomez-Isla T, Ribe E, Cuadrado M, Torrejon-Escribano B, et al. (2004) Expression of stress-activated kinases c-Jun N-terminal kinase (SAPK/JNK-P) and p38 kinase (p38-P), and tau hyperphosphorylation in neurites surrounding betaA plaques in APP Tg2576 mice. Neuropathol Appl Neurobiol 30: 491-502.
49. Lipinski MM, Yuan J (2004) Mechanisms of cell death in polyglutamine expansion diseases. Curr Opin Pharmacol 4: 85-90.
50. Ge B, Gram H, Di Padova F, Huang B, New L, et al. (2002) MAPKKIndependent Activation of p38alpha Mediated by TAB1-Dependent Autophosphorylation of p38alpha. Science 295: 1291-1294.
51. Wang X, McGowan CH, Zhao M, He L, Downey JS, et al. (2000) Involvement of the MKK6-p38gamma Cascade in gamma-Radiation-Induced Cell Cycle Arrest. Mol Cell Biol 20: 4543-4552.
52. Orr HT (2000) The ins and outs of a polyglutamine neurodegenerative disease: spinocerebellar ataxia type 1 (SCA1). Neurobiol Dis 7: 129-134.
53. van de Warrenburg BP, Verbeek DS, Piersma SJ, Hennekam FA, Pearson PL, et al. (2003) Identification of a novel SCA14 mutation in a Dutch autosomal dominant cerebellar ataxia family. Neurology 61: 1760-1765.
54. Chuanshu Huang JL, Nanyue Chen, Wei-ya Ma, G. Tim Bowden, Zigang Dong (2000) Inhibition of atypical PKC blocks ultraviolet-induced AP-1 activation by specifically inhibiting ERKs activation. Molecular Carcinogenesis 27: 65-75.
55. Xie J, Guo Q, Zhu H, Wooten MW, Mattson MP (2000) Protein kinase C iota protects neural cells against apoptosis induced by amyloid [beta]-peptide. Molecular Brain Research 82: 107-113.
56. Xie J, Guo Q (2005) PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein. J Biol Chem 280: 13824-13832.
57. Guo Q, Xie J, Chang X, Du H (2001) Prostate Apoptosis Response-4 Enhances Secretion of Amyloid beta Peptide 1-42 in Human Neuroblastoma IMR-32 Cells by a Caspase-dependent Pathway. J Biol Chem 276: 16040-16044.
58. Guo Q, Xie J (2004) AATF Inhibits Aberrant Production of Amyloid {beta} Peptide 1-42 by Interacting Directly with Par-4. J Biol Chem 279: 4596-4603.
59. Xie J, Chang X, Zhang X, Guo Q (2001) Aberrant induction of Par-4 is involved in apoptosis of hippocampal neurons in presenilin-1 M146V mutant knock-in mice. Brain Research 915: 1-10.
60. Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimaraes A, et al. (2006) Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 97: 151-161.
61. Subramaniam S, Unsicker K (2006) Extracellular signal-regulated kinase as an inducer of non-apoptotic neuronal death. Neuroscience 138: 1055-1065.
62. Subramaniam S, Zirrgiebel U, von Bohlen und Halbach O, Strelau J, Laliberte C, et al. (2004) ERK activation promotes neuronal degeneration predominantly through plasma membrane damage and independently of caspase-3. J Cell Biol 165: 357-369.
63. Cheung ECC, Slack RS (2004) Emerging Role for ERK as a Key Regulator of Neuronal Apoptosis. Sci STKE 2004: pe45-.
64. Luca Colucci-D'Amato CP-C, Umberto di Porzio (2003) Chronic activation of ERK and neurodegenerative diseases. BioEssays 25: 1085-1095.
65. Skinner PJ, Vierra-Green CA, Clark HB, Zoghbi HY, Orr HT (2001) Altered trafficking of membrane proteins in purkinje cells of SCA1 transgenic mice. Am J Pathol 159: 905-913.
66. Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, et al. (2003) H2o2 and 4-hydroxynonenal mediate amyloid [beta]-induced neuronal apoptosis by activating jnks and p38mapk. Experimental Neurology 180: 144-155.
67. Sahara N, Vega IE, Ishizawa T, Lewis J, McGowan E, et al. (2004) Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins. Journal of Neurochemistry 90: 829-838.
68. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, et al. (2002) [beta]-Amyloid-Induced Inflammation and Cholinergic Hypofunction in the Rat Brain in Vivo: Involvement of the p38MAPK Pathway. Neurobiology of Disease 11: 257-274.
69. Tortarolo M, Veglianese P, Calvaresi N, Botturi A, Rossi C, et al. (2003) Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci 23: 180-192.
70. Holasek SS, Wengenack TM, Kandimalla KK, Montano C, Gregor DM, et al. (2005) Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. Brain Research 1045: 185-198.
71. Ackerley S, Grierson AJ, Banner S, Perkinton MS, Brownlees J, et al. (2004) p38[alpha] stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Molecular and Cellular Neuroscience 26: 354-364.
72. Hildesheim J, Awwad RT, Fornace AJ Jr. (2004) p38 Mitogen-activated protein kinase inhibitor protects the epidermis against the acute damaging effects of ultraviolet irradiation by blocking apoptosis and inflammatory responses. J Invest Dermatol 122: 497-502.
73. Jochen Zwerina SH, Kurt Redlich, Klaus Bobacz, Giorgos Kollias, Josef S. Smolen, Georg Schett (2006) Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis & Rheumatism 54: 463-472.
74. Branger J, van den Blink B, Weijer S, Gupta A, van Deventer SJ, et al. (2003) Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 101: 4446-4448.
75. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, et al. (2002) Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 168: 4070-4077.
76. van den Blink B, Branger J, Weijer S, Gupta A, van Deventer SJ, et al. (2004) P38 mitogen activated protein kinase is involved in the downregulation of granulocyte CXC chemokine receptors 1 and 2 during human endotoxemia. J Clin Immunol 24: 37-41.
77. Block ML, Hong JS (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 76: 77-98.
78. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, et al. (2002) Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11: 1137-1151.
79. Nucifora FC Jr., Sasaki M, Peters MF, Huang H, Cooper JK, et al. (2001) Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. Science 291: 2423-2428.
80. McCampbell A, Taylor JP, Taye AA, Robitschek J, Li M, et al. (2000) CREBbinding protein sequestration by expanded polyglutamine. Hum Mol Genet 9: 2197-2202.
81. Cong S-Y, Pepers BA, Evert BO, Rubinsztein DC, Roos RAC, et al. (2005) Mutant huntingtin represses CBP, but not p300, by binding and protein degradation. Molecular and Cellular Neuroscience 30: 12-23.
82. Chiang M-C, Lee Y-C, Huang C-L, Chern Y (2005) cAMP-response Element-binding Protein Contributes to Suppression of the A2A Adenosine Receptor Promoter by Mutant Huntingtin with Expanded Polyglutamine Residues. J Biol Chem 280: 14331-14340.
83. Poizat C, Puri PL, Bai Y, Kedes L (2005) Phosphorylation-Dependent Degradation of p300 by Doxorubicin-Activated p38 Mitogen-Activated Protein Kinase in Cardiac Cells. Mol Cell Biol 25: 2673-2687.
84. Tsirigotis M, Tang MY, Beyers M, Zhang M, Woulfe J, et al. (2006) Delayed spinocerebellar ataxia in transgenic mice expressing mutant ubiquitin. Neuropathology and Applied Neurobiology 32: 26-39.
85. Kariya S, Hirano M, Uesato S, Nagai Y, Nagaoka Y, et al. (2006) Cytoprotective effect of novel histone deacetylase inhibitors against polyglutamine toxicity. Neuroscience Letters 392: 213-215.
86. Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, et al. (2004) Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 13: 1183-1192.
87. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. PNAS 100: 2041-2046.
88. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. 413: 739-743.
89. Rouaux C, Loeffler J-P, Boutillier A-L (2004) Targeting CREB-binding protein (CBP) loss of function as a therapeutic strategy in neurological disorders. Biochemical Pharmacology Proceedings from the 6th and 7th international conferences, Signal Transduction 2004 and Chromatin 2004 68: 1157-1164.